Indication:HIV- enhancer of the human immunodeficiency virus-1 (HIV-1) protease inhibitors atazanavir and darunavir in adults. Update 2020 – The licensed indication has been extended to include adolescents aged 12 years and older, weighing at least 35 kg when co-administered with atazanavir or weighing at least 40 kg when co-administered with darunavir, for the treatment of HIV-1.
Drug Safety Update
Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
Dec 2016 1.